MORNIFLUMATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H20F3N3O3
Molecular Weight	395.3756
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)(F)C1=CC(NC2=NC=CC=C2C(=O)OCCN3CCOCC3)=CC=C1

InChI

InChIKey=LDXSPUSKBDTEKA-UHFFFAOYSA-N

InChI=1S/C19H20F3N3O3/c20-19(21,22)14-3-1-4-15(13-14)24-17-16(5-2-6-23-17)18(26)28-12-9-25-7-10-27-11-8-25/h1-6,13H,7-12H2,(H,23,24)

HIDE SMILES / InChI

Molecular Formula	C19H20F3N3O3
Molecular Weight	395.3756
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1796197 | https://www.ncbi.nlm.nih.gov/pubmed/25921871

Morniflumate is a non-steroidal anti-inflammatory drug and represent as a beta-morpholinoethyl ester of niflumic acid, which is rapidly hydrolyzed in the plasma, releasing the free acidic form, the molecule responsible for the pharmacological effects. It was shown, that morniflumate was effective in the treatment of chronic recurring bronchitis and inhibited cyclooxygenase-1, 2 (COX-1, 2). Morniflumate has a 30-year history of clinical use, particularly for the treatment of pain associated with pediatric ear-nose-throat (ENT) infection. In addition, it appears to be a valid and well-tolerated alternative to other NSAIDs, or to antibiotics, for the treatment of pain and other symptoms of soft tissue inflammation.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase 89 Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27841153	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Chronic recurring bronchitis 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1796197	Primary	Phase II 1132	Unknown Approved Use Unknown
Paediatric ear-nose-throat (ENT) infection 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25921871	Palliative	Not Provided 504	Unknown Approved Use Unknown
Soft tissue inflammation 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25921871	Palliative	Not Provided 504	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
A gastroprotective anti-inflammatory agent: the beta-morpholinoethyl ester of niflumic acid (morniflumate).	1984 Feb	6608862
[A new anti-inflammatory-analgesic-antipyretic, morniflumate, in the treatment of chronic recurring bronchitis].	1991 Feb-Apr	1796197
Modulation of arachidonic acid metabolism by orally administered morniflumate in man.	1991 Jul	1659152
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
Drug use in children: cohort study in three European countries.	2008 Nov 24	19029175
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443

Patents

Sample Use Guides

In Vivo Use Guide

Comparative pharmacokinetic and bioequivalence evaluation of two formulations of morniflumate 350-mg tablets: single dose of 350-mg tablet

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:40:56 UTC 2023` Edited by `admin` on `Fri Dec 15 15:40:56 UTC 2023`
Record UNII	R133MWH7X1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MORNIFLUMATE

Official Name

English

NIFLUMIC ACID .BETA.-MORPHOLINOETHYL ESTER [MI]

Common Name

English

morniflumate [INN]

Common Name

English

MORNIFLUMATE [MART.]

Common Name

English

MORNIFLUMATE [USAN]

Common Name

English

3-PYRIDINECARBOXYLIC ACID, 2-((3-(TRIFLUOROMETHYL)PHENYL)AMINO)-, 2-(4-MORPHOLINYLETHYL) ESTER

Common Name

English

UP-164

Code

English

UP 164

Code

English

NIFLUMIC ACID .BETA.-MORPHOLINOETHYL ESTER

Common Name

English

Morniflumate [WHO-DD]

Common Name

English

2-MORPHOLINOETHYL 2-(A,A,A-TRIFLUORO-M-TOLUIDINO)NICOTINATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C28394